| Name | Title | Contact Details |
|---|---|---|
Yuhong Qiu |
VP, Regulatory Affairs | Profile |
Jim Pepin |
General Counsel | Profile |
Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. Selvita is also a major shareholder in Ardigen – a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine. In January 2021, Selvita acquired 100% of shares in Fidelta d.o.o., substantially expanding its scope of drug discovery services in infectious diseases, inflammation, and fibrosis and building a competitive advantage in areas such as DMPK, in vivo pharmacology, and toxicology. Selvita was established in 2007 and currently employs almost 800 professionals, of which over 40% hold a Ph.D. title. Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland, while Fidelta is located in Zagreb, Croatia. Selvita`s international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.
Fastgen Corporation is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spun out of MIT in 2006, Cambrian Innovation is commercializing a portfolio of environmental solutions based on newly discovered electrically active microbes. By harnessing the power of bio-electricity and advances in electrochemistry, Cambrian Innovation`s products help industrial, agricultural, and government customers save money while recovering clean water and clean energy from wastewater streams. Our bio-electrogenic sensor platform enables low-cost, real-time monitoring of critical natural resources. At Cambrian Innovation our vision is simple: Industry is an ecosystem. Because the biological world is by definition sustainable, creative application of biological engineering is the best way to solve our most pressing environmental challenges. Cambrian Innovation`s solutions leverage advances in bio-electricity to help industrial and agricultural customers cut costs while meeting their environmental goals.
Mixture Sciences Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Avidity Biosciences, Inc.`s mission is to profoundly improve people`s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity`s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity`s advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA.